Rein Therapeutics (NASDAQ:RNTX) Upgraded to “Hold” at Wall Street Zen

Rein Therapeutics (NASDAQ:RNTX) was upgraded by stock analysts at Wall Street Zen to a “hold” rating in a report released on Saturday.

A number of other research firms also recently commented on RNTX. Weiss Ratings reiterated a “sell (e+)” rating on shares of Rein Therapeutics in a report on Wednesday, October 8th. HC Wainwright initiated coverage on Rein Therapeutics in a research note on Monday, September 22nd. They issued a “buy” rating and a $10.00 price target for the company. Brookline Capital Management raised shares of Rein Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, November 3rd. Finally, Loop Capital set a $6.00 price target on shares of Rein Therapeutics in a research report on Monday, November 3rd. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $8.00.

Rein Therapeutics Stock Performance

Shares of RNTX stock opened at $1.36 on Friday. The firm’s 50 day moving average price is $1.38 and its two-hundred day moving average price is $1.43. Rein Therapeutics has a 52-week low of $1.04 and a 52-week high of $3.50. The stock has a market cap of $35.75 million, a PE ratio of -0.52 and a beta of 1.27.

Rein Therapeutics (NASDAQ:RNTX) last issued its earnings results on Friday, November 14th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.03. As a group, sell-side analysts predict that Rein Therapeutics will post -1.56 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, major shareholder Voss Capital, Lp purchased 178,392 shares of Rein Therapeutics stock in a transaction dated Tuesday, October 28th. The stock was bought at an average price of $1.39 per share, for a total transaction of $247,964.88. Following the completion of the acquisition, the insider directly owned 500,000 shares of the company’s stock, valued at $695,000. This represents a 55.47% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have purchased a total of 410,233 shares of company stock valued at $550,563 over the last 90 days. Insiders own 5.10% of the company’s stock.

Institutional Investors Weigh In On Rein Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Blair William & Co. IL bought a new stake in Rein Therapeutics in the 2nd quarter valued at $33,000. Chicago Partners Investment Group LLC bought a new stake in shares of Rein Therapeutics in the second quarter valued at about $64,000. Exencial Wealth Advisors LLC acquired a new position in shares of Rein Therapeutics during the second quarter worth about $43,000. University of Texas Texas AM Investment Management Co. acquired a new position in shares of Rein Therapeutics during the second quarter worth about $716,000. Finally, Sigma Planning Corp bought a new position in shares of Rein Therapeutics during the second quarter worth about $387,000. 90.89% of the stock is currently owned by institutional investors and hedge funds.

Rein Therapeutics Company Profile

Rein Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers.